DXRX vs. AGL, SCLP, BVC, EAH, SPEC, CEL, POLB, KOO, REDX, and CREO
Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Scancell (SCLP), BATM Advanced Communications (BVC), ECO Animal Health Group (EAH), INSPECS Group (SPEC), Celadon Pharmaceuticals (CEL), Poolbeg Pharma (POLB), Kooth (KOO), Redx Pharma (REDX), and Creo Medical Group (CREO). These companies are all part of the "medical" sector.
ANGLE (LON:AGL) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
In the previous week, ANGLE and ANGLE both had 3 articles in the media. ANGLE's average media sentiment score of 0.07 beat Diaceutics' score of 0.00 indicating that Diaceutics is being referred to more favorably in the news media.
Diaceutics has higher revenue and earnings than ANGLE.
ANGLE presently has a consensus price target of GBX 70, suggesting a potential upside of 241.46%. Diaceutics has a consensus price target of GBX 150, suggesting a potential upside of 31.00%. Given Diaceutics' higher probable upside, research analysts clearly believe ANGLE is more favorable than Diaceutics.
ANGLE has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
ANGLE received 172 more outperform votes than Diaceutics when rated by MarketBeat users. However, 81.82% of users gave Diaceutics an outperform vote while only 62.20% of users gave ANGLE an outperform vote.
Diaceutics has a net margin of 0.03% compared to Diaceutics' net margin of 0.00%. ANGLE's return on equity of 0.01% beat Diaceutics' return on equity.
27.2% of ANGLE shares are owned by institutional investors. Comparatively, 53.2% of Diaceutics shares are owned by institutional investors. 10.7% of ANGLE shares are owned by insiders. Comparatively, 34.5% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Diaceutics beats ANGLE on 11 of the 14 factors compared between the two stocks.
Get Diaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Diaceutics Competitors List
Related Companies and Tools
